Skip to main
MTVA

MTVA Stock Forecast & Price Target

MTVA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MetaVia is a clinical-stage biotechnology company with a promising pipeline targeting cardiometabolic diseases, specifically MASH and obesity. The company's novel compound, Vanoglipel (DA-1241), has shown potential as a standalone or combination therapy for both MASH and Type 2 Diabetes. In addition, the company has reported positive data for its obesity treatment, DA-1726, and has a strong financial position with $13.7 million in cash as of March 31, 2026. Risks for investors include the potential for disappointing data, failure to identify a treatment combination for DA-1241, and delays in development timelines. Overall, MetaVia has a positive outlook with multiple potential growth drivers in its pipeline.

Bears say

MetaVia is in a critical phase of development, with key data events expected in 4Q26 for both the Phase 1 Part 3 program for DA-1726 and the FDA end-of-Phase 2 meeting for vanoglipel. However, concerns remain around the potential differentiation of DA-1726's effects and the company's financials, with a heavy reliance on the upcoming data and potential need for further financing. It will be crucial to assess the data in the context of competitive peers to determine the likelihood of success and potential for market differentiation.

MTVA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroBo Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroBo Pharmaceuticals Inc (MTVA) Forecast

Analysts have given MTVA a Strong Buy based on their latest research and market trends.

According to 1 analysts, MTVA has a Strong Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroBo Pharmaceuticals Inc (MTVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.